Alternative explanations for T-cell response to in-situ gene therapy for prostate cancer: in reply to Fujita et al. (Int J Radiat Oncol Biol Phys 2006;65:84-90).
Millar
Jeremy Laurence
JL
Sutherland
Jayne S
JS
Boyd
Richard L
RL
D000726:Androgen Antagonists / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003131:Combined Modality Therapy / Q000379:methods; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D012038:Regeneration / Q000502:physiology*; D013950:Thymus Gland / Q000276:immunology / Q000502:physiology*
D000726:Androgen Antagonists